Healthy carriers of hepatitis C virus (HCV) infection exhibit a specific antibody response against all HCV antigens, which could play a role in disease control. Generation of panels of human antibodies may permit a thorough characterization of this response and further identify particular antibodies with potential clinical value. To this effect, we have established a human phage-display antibody library from a patient exhibiting a high antibody response against HCV antigens and no clinical symptoms of disease. This library was screened against a recombinant core antigen [amino acids (aa) 1-119] produced in E. coli. Two recombinant Fab-carrying phages (rFabCs) were isolated and characterized. Both rFabC3 and rFabC14 recognize aa 1-48 on core antigen, but rFabC14 is competed out by a synthetic peptide, C 2-20 (aa 1-20), at much lower concentrations than rFabC3. In order to identify more precisely the recognition sites of these antibodies, we produced soluble forms of the rFabs (sFabs), and used them to pan a random phage-display peptide library. A single peptide sequence, QLITKPL, was identified with sFabC3, while two equally represented sequences, HAFPHLH and SAPSSKN, were isolated using sFabC14. The QLITKPL sequence was partially localized between aa 8 and 14 of core protein, but no clear homology was found for the two sFabC14 peptides. However, we confirmed the specificity of these peptides by competition experiments with sFabC14.
Introduction
Hepatitis C virus (HCV), an enveloped positive-strand RNA virus, is the major aetiological agent for non-A, non-B hepatitis. It is known to be implicated in chronic liver infection, and later complications lead to liver cirrhosis and hepatocellular carcinoma (Choo et al., 1989 (Choo et al., , 1990 . The virus is mainly blood-transmitted, and immunity against it appears to be only partially effective, since a chronic infection is established in about two-thirds of patients (Choo et al., 1990 ; van der Poel, 1994) . Chronically infected patients are Author for correspondence : Veronique Barban.
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characterized by fluctuating levels of liver enzymes, mainly alanine aminotransferase (ALT), a broad antibody response against viral antigens and presence of virus in blood, as evidenced by RT-PCR . Screening of blood donors has also revealed that patients who test positive for anti-HCV antibodies sometimes have normal ALT levels, despite a transient or fluctuating viraemia, and could be healthy carriers of HCV (Romeo et al., 1993 ; Yuki et al., 1994) .
The main target for HCV diagnosis is the structural nucleocapsid protein. This protein is well conserved among different HCV genotypes (Bukh et al., 1994) and anti-capsid antibodies are present in the majority of patients with chronic infection (Harada et al., 1991 ; Manzini et al., 1993) . As an example, the recombinant C22-3 protein, spanning amino acids (aa) 2-120 of the nucleocapsid protein, is the major component of the commercially available second-generation anti-HCV tests (Chemello et al., 1993 ; Hosein et al., 1991) .
The capsid gene is located at the 5h end of the genome. A large unique polyprotein precursor (Grakoui et al., 1993 a, b, c ; Manabe et al., 1994 ; Tanji et al., 1994) is directly translated from the viral RNA (Choo et al., 1989) and post-translationally processed by both host and viral proteases (Hijikata et al., 1993 ; Manabe et al., 1994) . Structural proteins, including capsid (C) and two envelope proteins (E1 and E2), are generated by sequential cleavages in the first one-third of the polyprotein, while non-structural proteins (NS2, NS3, NS4 and NS5) are generated from the remaining two-thirds.
Several studies, based on scanning of the protein with synthetic peptides, have indicated that the HCV capsid protein contains multiple linear, highly immunogenic epitopes (Akatsuka et al., 1993 ; Cerino et al., 1993 ; Chiba et al., 1991 ; Ferroni et al., 1993 ; Goeser et al., 1994 ; Moradpour et al., 1996 ; Nasoff et al., 1991 ; Pujol et al., 1996 ; Sallberg et al., 1992 Sallberg et al., , 1994 Yoshikawa et al., 1992) . Conversely, very little is known about naturally occurring nucleocapsid conformational epitopes, mainly because only a few antibodies have been recovered from HCV-infected individuals (Akatsuka et al., 1993 ; Cerino et al., 1993 ; Siemoneit et al., 1994 b) .
In recent years, the phage display system, originally developed by Parmley & Smith (1988) for peptide library presentation and identification of epitopes, has been widely applied to express antibody fragments on the phage surface (for a review see Winter et al., 1994) . This process may be considered as a powerful alternative to the hybridoma technology of Kohler & Milstein (1975) . Human antibody libraries can be generated by random combinatorial linkage of diverse repertoires of V H and V L genes from lymphocytes (Barbas et al., 1991 ; Burton & Barbas, 1994 ; Clackson et al., 1991 ; Hoogenboom et al., 1992 ; Huse et al., 1989 ; Lerner et al., 1992 ; Marks et al., 1992 ; McCafferty et al., 1990 ; Waterhouse et al., 1993) . Antibody fragments are displayed on the surface of phage fd fused to a minor coat protein (pIII), and specific antibodies are obtained by sequential rounds of selection (biopanning) on variously presented antigens (Griffiths et al., 1994 ; Williamson et al., 1993) .
In this paper, we present the construction of a combinatorial human antibody library from an HCV-positive non-symptomatic patient, and the isolation and characterization of specific recombinant Fabs directed against core antigen. By screening a synthetic peptide library, we also show that one of these Fabs defines a new human B cell epitope within the immunodominant N-terminal region of the HCV nucleocapsid.
Methods
Core recombinant antigens and peptides. HCV cDNA fragments representing the N-terminal core protein region (aa 1-48 and aa 1-119 in the HCV genome, C " -%) and C " -""* , respectively) of the HCV 1a strain (Choo et al., 1989) were generated by PCR and cloned into E. coli expression plasmid pET21b (Novagen) followed by a hexahistidine tail. Bacterial cultures were induced by adding IPTG (GIBCO-BRL) to a final concentration of 0n4 mM. Cells were harvested by centrifugation and 
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, aa 38-81) or derived from phage, were prepared at bioMe! rieux using standard solid-phase synthesis procedures (Barany & Merrifield, 1980) and were purified by high-performance liquid chromatography (HPLC). The purity of the peptides was more than 90 % after analysis by mass spectrometry.
Human sera. Serum 1 was obtained from a 35-year-old female blood donor woman who had been anti-HCV positive for at least 5 years but had normal ALT levels and no clinical symptoms of disease. Viral genome was transiently detected in blood by RT-PCR (Simmonds et al., 1993) , and corresponded to HCV genotype 1a (Bukh et al., 1992) . Serological studies with the Innolia AbIII diagnostic kit (Innogenetics) showed strong reactivity against all HCV antigens except NS5, suggesting that HCV infection is immunologically regulated in this patient (Table 1) . Serum 2 was obtained from a chronic carrier, successfully treated with IFN-α for 18 months. Six months after the end of the treatment, this patient exhibited normal ALT and was RT-PCR negative. Serum 2 exhibits a clear reactivity against HCV antigens in the RIBA-2 assay (Chiron), with the Innolia AbIII diagnostic kit and in ELISA against core antigen. Serum 3 was obtained from a patient who developed acute hepatitis, confirmed by RT-PCR, after an accidental needle stick injury. Seroconversion (RIBA-2 assay) was observed and the patient was treated with IFN for 3 months. At the end of the treatment the patient exhibited normal ALT and was RT-PCR negative, suggesting that a chronic infection was not successfully established. Serum 3 is positive in RIBA-2, but reacts only partially in Innolia AbIII against non-structural proteins NS3 and NS4. No reactivity against core antigens has been observed, either in Innolia AbIII or by ELISA.
Fab library construction. The Fab library was established using standard procedures (Smith & Scott, 1993) . Briefly, a 100 ml blood sample was harvested in heparinized tubes. Peripheral blood lymphocytes (PBL) were separated on Ficoll MSL (Eurobio). Messenger RNAs were extracted and reverse transcribed into cDNAs. Heavy (V H ) and light (V L ) chain variable regions were PCR-amplified in a two-step PCR strategy (Sodoyer et al., 1997) . The first step was performed using previously described family-based primers (Huse et al., 1989) . which have been modified by 5h addition of a 19 bp tail sequence, allowing reamplification with a unique primer (' fog ' primer 5h CGGGGCGGGATGATAGCT 3h)
Human epitope in HCV core protein Human epitope in HCV core protein complementary to the tail sequence, as in Sodoyer et al. (1997) . Amplified V H and V L fragments were introduced into phagemid pM831 and plasmid pM452, respectively (Sodoyer et al., 1997) , to generate V H and V L libraries. The two repertoires were then associated by subcloning V L genes into the V H library. Fab-displaying phages were recovered by infecting an exponential culture of the phagemid library with M13 VCS helper phage (Stratagene), as previously described (Ames et al., 1994) .
Panning of libraries.
For panning of the Fab library, immunotubes (Maxisorp, Nunc) were coated with C " -""* recombinant antigen at a concentration of 1 mg\ml, for 1 h at 37 mC, blocked in 5 % non-fat milk in PBS, and incubated with 5i10"" phages for 2 h at 37 mC. Several washes in PBS-0n05 % Tween 20 (PBS-T) were performed as described in Engberg et al. (1995) , and specific phages were eluted with 500 µl 100 mM triethanolamine for 15 min. The pH was decreased to neutrality by adding 100 µl 1 M Tris-HCl pH 7 and eluted phages were amplified in E. coli XL-1 Blue strain (Stratagene). After concentration and titration, 10"" phages were used for another round of panning. Four successive rounds were performed in this way. Panning of the peptide library (pHD7, New England Biolabs) was performed as recommended by the manufacturer. Washes, elution and amplification of specific phages were done as described above (this section). At the third and fourth round, the eluted phages were titrated and 12 individual plaques were picked and amplified in E. coli. Phage DNA minipreparations were performed using standard M13 procedures and DNA was sequenced on an automated sequencer (LI-COR), according to the manufacturer's instructions.
Anti-phage ELISA. Antigen solutions were coated onto an enzyme immunoassay microtitration plate at 1 or 2 mg\ml, depending on the antigen, and the plate was incubated for 16 h at 4 mC. Goat anti-human Fab IgGs (Sigma), C "
-""* and C " -%) recombinant antigens were diluted to 1 µg\ml in PBS ; core-derived peptides were diluted to 5 µg\ml in PBS. Wells were then blocked for 1 h in 5 % non-fat milk in PBS, 10*-10"! phages in PBSj1 % non-fat milk added and the mixture incubated for 2 h at 37 mC. After extensive washing with PBS-T, 100 µl anti-fd bacteriophage biotin conjugate (Sigma) diluted to 1 : 2000 was added to each well for an additional 1 h of incubation at 37 mC. After another round of extensive washes in PBS-T, plates were incubated for 10 min with streptavidin biotinylated horseradish peroxidase complex (Amersham). The reaction was then developed for 45 min with o-phenylenediamine as substrate and stopped with 50 µl 1 M sulfuric acid before reading on an automated system equipped with a 492 nm filter (Multiscan Titertek, ICN Flow). Results are expressed as the ratio of relative absorbance on specific antigen to relative absorbance on anti-human Fab, after deduction of background absorbance.
Competition experiments. For inhibition of binding experiments, a phage dilution which results in approximately 40 % reduction of the absorbance value after twofold serial dilutions on antigen-coated plates was mixed with serial tenfold dilutions of peptides in PBS. For competition experiments, the phage dilution which results in approximately 80 % reduction of the absorbance value in the same conditions was mixed with twofold serial dilutions of human antisera in PBS. These mixtures were tested in a standard anti-fd ELISA. Values are expressed as a percentage of the relative A %*! absorbance obtained with the same quantity of phages incubated without competing peptides or sera.
Construction and purification of soluble Fabs. Phagemid DNA was digested with SpeI and NheI (10-40 U\µl, Boehringer Mannheim) to excise gene III, gel-purified, and cohesive ends ligated to allow expression of a His-tailed V H gene. This construction lead to the insertion of two extra amino acids (a tyrosine and a serine) between the His tail and the N terminus of the V H region. A 2 l fermenter of TGM-16 broth containing carbenicillin (50 µg\ml) and MgCl # (20 mM) was inoculated with a preculture of the appropriate clone. Secretion of soluble rFabs (sFabs) was induced, when the culture reached an OD '!! of 0n6, with 1 mM IPTG for 8 h at 37 mC. Cells were collected by centrifugation (Beckman J-6B ; 3000 g, 45 min, 4 mC) and the supernatant fraction was removed. The cell pellet was resuspended in 1\20 of the original volume of PBS and submitted to four rounds of freezing (liquid nitrogen) and thawing (56 mC). After centrifugation (Beckman J-21B ; 10 000 g, 30 min, 4 mC), the supernatant was recovered and dialysed overnight against 50 mM Tris-HCl, 500 mM NaCl, pH 8n0. The filtered (0n45 µm) supernatant was loaded on a 5 ml HiTrap chelating column. (Pharmacia), washed with dialysis buffer and eluted with 50 mM Tris-HCl, 500 mM NaCl, 500 mM imidazole, pH 8n0 (1 ml\min). Eluted fractions were pooled, dialysed against PBS overnight at 4 mC, concentrated (Centricon 3, Millipore), and then analysed by SDS-PAGE (Phast system, Pharmacia) according to the manufacturer's instructions, and by Western blot using a light chain-specific anti-human IgG (Fab) (data not shown). Purity was around 80 %. Culture yields were in the order of 5 mg\l for sFabC3, and 0n8 mg\litre for sFabC14. This difference is probably due to toxicity of sFabC14 when over-produced in bacteria. Indeed, we observed a clear inhibition of bacterial growth after induction with IPTG. The sFab concentration was determined in a sandwich ELISA by comparison with known concentrations of purified human IgG (Fab) fragment, and compared to the total protein concentration of the sample.
Results

Molecular cloning of the antibody repertoire of a nonsymptomatic, HCV antibody-positive patient
The characteristics of the serum are described in Table 1 . The library was established using PBLs as starting material. A heavy and a light chain library were first constructed with complexities of 0n7i10' (heavy γ) and 2i10' (light λ plus κ), respectively. Sequencing of randomly selected clones revealed an equivalent representation of different isotypes of γ 1, λ and κ chains (data not shown). In the final construct, V H and V L genes are expressed independently under the control of the lacZ promoter, V H being fused with p3. The diversity of this library is 1n1i10(, and production of Fab-expressing phages after helper phage infection was checked by ELISA using a goat anti-human Fab as antigen (not shown).
Panning of the surface library against C 1-119 antigen
The phage surface expression library was panned against a core-derived recombinant antigen (C " -""* , aa 1-119) coated on immunotubes. We used a truncated form, deleted from the Cterminal hydrophobic region, and purified after solubilization in 1 M guanidium.HCl, in order to break core recombinant antigen-nucleic acid interactions. This truncated antigen is very similar to C22 (aa 2-120), which was a component of the first generation diagnostic kits. Recombinant phages were analysed by anti-fd ELISA. As it is difficult to control Fab surface expression on phage [it is commonly considered that only 1-10 % of phages actually carry an Fab molecule at their surface, due to proteolysis (Hoess et al., 1994) ], the anti-fd ELISA assay was standardized by incubating the phage minipreparations on anti-human Fab (light chain-specific)-EGD V. Barban and others V. Barban and others coated plates, and expressing the results as the ratio of specific absorbance of HCV antigen to anti-human Fab.
Twelve out of eighteen (70 %) isolated Fab-carrying phages (rFabCs) from panning 4 were specific for C " -""* recombinant antigen in this ELISA and were further analysed for their ability to recognize C " -""* -derived polypeptides. Only two different clones were identified, on the basis of sequence analysis : a major one, rFabC14 (11\12 clones), and a minor one, rFabC3 (1\12). These two clones recognize C " -%) (aa 1-48) recombinant antigen, but not C $) -)" (aa 38-81) (Fig. 1 ). More precisely, phage rFabC3 recognizes C # -#! (aa 2-21) peptide, while no significant reactivity against either C # -#! or C ## -%& (aa 22-45) peptides was observed with rFabC14. To test the hypothesis that rFabC14 could recognize a linear epitope overlapping C # -#! and C ## -%&, reactivity of this recombinant was assayed on peptide C ") -#% (aa 18-24), which is known to contain an immunodominant epitope (Jolivet-Reynaud et al., 1998) . No significant reactivity was observed (A %(! l 0n040 with 10"" phages ; not shown). This may indicate that rFabC14 is directed against a conformation-dependent epitope present on C " -%) but not present on the derived peptides. We cannot exclude, however, that coating of these uncoupled peptides to plastic drastically affects their conformation, as suggested by Chan et al. (1996) from similar observations, leading to an absence of reactivity.
The complete nucleotide sequence of immunoglobulin domains carried by rFabC3 and rFabC14 was established and can be obtained from the EMBL database (accession nos AJ251251-53, AJ251291). The two recombinant Fabs present a V H 3 heavy chain, associated to a κ4 (rFabC3) or a λ1 (rFabC14) light chain. The V-segments derive from previously described germline genes and contain amino acid differences, apart from V κ 4 segment of rFabC3 which is identical to DPK-24 segment. V H segments are derived from DP-31 and DP-38 germline sequences, and V L -segments are derived from DPL-5 and DPK-24 sequences, for rFabC14 and rFabC3, respectively.
Competition with human sera
To confirm that the recombinant phages, rFabC3 and rFabC14, present anti-HCV-specific Fabs on their surface, they were tested for their ability to compete with human anti-HCVpositive sera for recognition of anti-C " -%) recombinant antigen. The initial serum from the patient whose antibody repertoire was cloned (serum 1) as well as two other anti-HCV-positive sera (sera 2 and 3) was independently tested. All three exhibit a clear reactivity against HCV antigens ; serum 1 and 2 also react against core epitopes, while serum 3 does not. Fig. 2 shows that serum 1 and serum 2, but not a pool of 10 sera from non-immune donors, are able to block the binding of the two Fab-carrying phages, rFabC3 and rFabC14, in a concentrationdependent manner. There is a correlation between the titres in ELISA against C " -%) and the ability to block the two rFabCs : serum 1 has an ELISA titre of 1 : 600, and complete inhibition is reached at a serum dilution of 1 : 16, while serum 2, with an ELISA titre of 1 : 200, completely inhibits rFabCs binding at a dilution of 1 : 4. Using serum 3 as a source of competing antibodies, we observed an incomplete, but significant, inhibition effect (around 20 % at dilution 1 : 2) of the binding of rFabC14 but not of rFabC3. This last result was unexpected considering that serum from this patient does not recognize capsid polypeptides in direct detection assays. It may indicate that serum 3 contains low, but significant, titres of antibodies with the same specificity as rFabC14.
Inhibition of binding of recombinant FabCs by peptides
Competition ELISA experiments were carried out using core-derived peptides as competitors. Tenfold dilutions of each polypeptide were mixed with a constant amount of Fabcarrying phages, and incubated on C " -%) recombinant antigencoated plates (Fig. 3) . Neither of the two recombinant phages was inhibited using C ## -%& or C ") -#% peptide as competitor. C # -#! soluble peptide was able to block rFabC3 binding in a dose-dependent manner and 50 % inhibition was achieved with concentrations of C # -#! peptide in the range 0n1-1 µM. C # -#! soluble peptide also clearly inhibits the binding of rFabC14. However, a lower concentration of C # -#! is necessary (50 % inhibition with doses ranging from 10 to 100 nM). This could be due to different levels of Fab expression at the surface of the two phages but previous ELISA titration of the recombinant phages on anti-human IgG (Fab fragment) revealed that there was no significant differences in the Fab concentration of the two preparations (11n6 ng and 10 ng per 10"# c.f.u. of rFabC3 and rFabC14 respectively). Thus, the fact that binding of EGE Human epitope in HCV core protein Human epitope in HCV core protein Fig. 2 . Blocking of rFabC3 and rFabC14 binding by human sera. The characteristics of the three sera are listed in the righthand panel. Serum 2 was obtained from a chronic patient, and serum 3 was obtained soon after seroconversion in a patient with a primary infection. A pool of sera from 10 non HCV-immune donors was used as negative control. 10 10 to 5n10 10 c.f.u. of each phage (indicated at the top of the graphs) was mixed with serial twofold dilutions of serum and incubated onto C 1-48 recombinant antigen-coated plates. Values on the abscissa correspond to serum dilutions ranging from 1 : 2 (value 1) to 1 : 1024 (value 10) after conversion into log 2 . Results are expressed as percentage of rFabC binding measured under identical conditions, but in the absence of competitor. Fig. 3 . Dose-dependent inhibition of binding of rFabC3 and rFabC14 by soluble peptides. C 2-20 peptide (open symbols) and C 22-45 peptide (filled symbols) were serially tenfold diluted, mixed with 5i10 9 to 10 10 c.f.u. of rFabC3 or rFabC14, and incubated onto C 1-48 recombinant antigen-coated plates. Values on the abscissa correspond to peptide concentrations ranging from 10 4 M − 1 (value k4) to 10 12 M − 1 (value k12), after log 10 conversion. Results are expressed as in Fig. 3. rFabC14 is inhibited at lower concentrations of C # -#! than that of rFabC3, probably reflects a higher affinity of rFabC14 for this peptide. We also deduced from this experiment that rFabC14 and rFabC3 recognized two different motifs in the region spanned by C # -#! peptide, the conformation of the motif recognized by rFabC14 being modified when the peptide is bound to solid phase.
To confirm these results, soluble forms of the recombinant FabCs, sFabC3 and sFabC14, were produced as described in Methods, and their ability to recognize core-derived peptides was checked in ELISA (50 % A %*! max was achieved at 1µg\ml for sFabC3 and 0n45 µg\ml for sFabC14 ; data not shown), and using the diagnostic assay Innolia HCV AbIII (Fig. 4) . In this EGF V. Barban and others V. Barban and others assay and under identical conditions, sFabC3 reacted with core peptides whereas sFabC14 did not. This result is consistent with what we had observed in ELISA against C # -#! peptide. Consequently, it appeared that further characterization of the human recombinant Fabs, based on HCV core-derived peptides, would probably provide only limited information.
Thus, we decided to use the more powerful strategy of screening a random, phage-displayed, peptide library. Such libraries have already proven their efficacy for identifying ligands for both linear and conformation-dependent antibodies (Felici et al., 1993 ; Folgori et al., 1994 ; Hoess et al., 1994 ; Lane & Stephen, 1993) . A commercially available phage-displayed peptide library (pHD7, NEB) was panned on sFabC3-and sFabC14-coated immunotubes. After panning against sFabC3, all isolates yielded an identical DNA sequence encoding the amino acid sequence QLITKPL. Two different, but equally represented DNA sequences, were identified after panning against sFab14, encoding the amino acid sequences HAFPHLH and SAPSSKN. Considering the large enrichment observed at the end of the selection process (1000-fold), we assumed that these sequences are sFab ligands. The sequence QLITKPL shares some common amino acids with the sequence QRKTKRN located between aa 8-14 of HCV core protein. No homology with HCV core sequence could be established for the two other peptides.
The identified peptide sequences were chemically synthesized. The C terminus was blocked in order to mimic the peptide link with pIII protein and to avoid modifications of the ionic charge of the peptides by introducing an extra negative charge. As shown in Fig. 5 , binding to C " -%) recombinant antigen of soluble Fabs, sFabC3 and sFabC14, can be completely inhibited by their respective synthetic peptides, but not by C ") -#% peptide. 50 % inhibition of sFabC3 was observed with concentration of QLITKPL and QRKTKRN peptides between 10& and 10' M −" . However, the natural peptide QRKTKRN was unable to inhibit more than 50 % of sFabC3 binding, suggesting that this peptide do not contain the entire epitope sequence recognized by sFabC3. A similar concentration was necessary to reach 50 % inhibition of sFabC14 using HAFPHLH peptide, while only 10(-10) M −" was necessary using SAPSSKN peptide, indicating that this sequence has a greater affinity for sFabC14 than the former. No inhibition of sFabC3 or sFab C14 was observed using a nonrelated peptide sequence with similar isoelectric point (not shown).
Discussion
Antibody library
Two human phage antibody libraries were previously independently established from antibody-positive HCV patients with clinical symptoms of disease : an scFv one with a complexity of 10( (Zhai et al., 1999 ; Chan et al., 1996) and an Fab one (Plaisant et al., 1997) with a complexity of 2i10'. Both have allowed isolation of anti-HCV specific clones. The Fab library we have established from a non-symptomatic patient is in the same order of complexity (2i10(). Such small repertoires have already been demonstrated to be an adequate source of high-affinity antibodies (Aujame et al., 1997) , when established from immunized individuals.
Only two different recombinant phages were selected at the end of the panning, one (rFabC14) being represented 10 times more than the other (rFabC3). This low number can be attributed to the panning conditions, especially washes, which were done in order to select high-affinity binders. These phages carry human antibody specificities naturally induced EGG during human infection, as demonstrated by inhibition of binding by human anti-HCV-positive sera, and we observed a correlation between anti-core serum titres and the level of inhibition. Such a correlation has been observed previously in a similar study with a recombinant scFv selected against a peptide scanning aa 66-88 on core protein. (Chan et al., 1996) . However, despite high serum titres of anti-peptide antibodies (1 : 12 800), complete inhibition of scFv binding was never observed (76 %), probably reflecting the fact that antigen presentation by small peptides is not optimal.
We found antibodies with the same specificity as FabC14 in serum 3. The serum of this patient does not contain any detectable antibody against major capsid epitopes, probably because the infection was not successfully established (possibly due to IFN treatment). Consequently, we deduced that FabC14-like antibodies could have appeared very early after infection. The absence of reactivity against core in Innolia assay is expected as FabC14 does not recognize any peptide in this assay, and we believe that the ELISA assay is not adapted for detection of low-abundant antibodies of these type.
Epitope mapping of the two recombinant antibodies
rFabC3 recognizes a linear epitope contained in the first 21 aa of the capsid molecule, as deduced from anti-C # -#! ELISA. Using overlapping peptides, several authors have described a linear epitope in this region, both in the murine and in the human system (Nasoff et al., 1991 ; Okamoto et al., 1992 ; Pujol et al., 1996 ; Jolivet-Reynaud et al., 1998) The sequence RKTKRNTN (aa 9-16) has been identified as a major antigenic site in humans and in chimpanzees (Sallberg et al., 1992 ; Wang et al., 1996) . The sequence QLITKPL that we isolated from the peptide library exhibits significant homology with the region QRKTKRN within aa 8-14. Both sequences are able to compete-out sFabC3 from recombinant antigen with similar concentrations, but competition is only partial with QRKTKRN peptide. We concluded from this experiment that the region between aa 8-14 is part of the epitope mimicked by QLITKPL sequence. However, sFabC3 has a low affinity for both peptides : we calculated that a 100-to 1000-fold molar excess of peptide is needed to reach maximum inhibition. We suggest that either neither of these two sequences contains the entire FabC3 epitope, or FabC3 is a low-affinity antibody. By further screening of the peptide library, higher-affinity sequences could be isolated which would help to discriminate between these two hypotheses.
Of the two peptide sequences we have identified as ligands for sFabC14, SAPSSKN is the one which exhibits the highest affinity for sFabC14 : complete inhibition of binding of the soluble Fab occurs in conditions of molar excess of peptide ranging from 1 to 10. However, this sequence shares no homology with the primary HCV core sequence, and we suggest that it could represent a mimotope of a conformationdependent epitope. The N-terminal region of the capsid contains multiple overlapping epitopes, and studies in the murine system as well as in humans suggest that there is at least one major conformational epitope residing within the first 82 aa of the HCV core protein (Cerino et al., 1993 ; Goeser et al., 1994 ; Moradpour et al., 1996 ; Nasoff et al., 1991) . More precisely, a conformational epitope has been previously identified by several teams in the region spanned by aa 20-45 (Cerino & Mondelli, 1991 ; Nasoff et al., 1991 ; Pujol et al., 1996 ; . However, there are no data about a conformational epitope being present in the region spanned within aa 2-21. Consequently, the epitope recognized by sFabC14 may represent a new human conformational epitope on HCV core protein.
Recombinant FabC14 does not recognize C # -#! peptide in ELISA, but it can be competed out from C " -%) recombinant antigen with low doses of the same peptide (10(-10) M −" ). This suggests that the two recombinant antibodies recognize either two different epitopes, or two regions, a structured and a non-structured one, which are parts of the same epitope. Only structural analysis will allow us to discriminate between these two possibilities, and further studies will include localization of SAPSSKN, HAFPHFL and QLITKPL peptides on the three-dimensional model of HCV core region " -%) , which has been recently deduced from NMR studies (Penin et al., 1997) .
Conclusions
The library reported in this paper represents an important tool for isolating specific antibodies against different HCV viral antigens, such as anti-envelope antibodies that are present at low titres in naturally infected individuals. The fact that HCV infection was naturally down-regulated for at least 5 years in the patient we chose encourages us in our effort to isolate anti-HCV neutralizing antibodies, which are of crucial interest for serotherapy or vaccine development.
